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A B S T R A C T
Prader–Willi syndrome (PWS) is a neurodevelopmental disorder caused by the loss of paternally expressed genes in an imprinted region of chromosome
15q11.2–q13. We generated a human-induced pluripotent stem cell line, designated KSCBi009-A, from peripheral blood mononuclear cells of a 13-year-old male PWS
patient exhibiting deletion of the paternal chromosome 15q11.2–q13 region. The deletion was confirmed via methylation-specific multiplex ligation probe ampli-
fication assay (MS-MLPA) of genomic DNA. The hiPSC line expressed pluripotency markers and differentiated into three germ layers. The cell line may serve as a
valuable model of an imprinting PWS disorder useful in terms of drug discovery and development.
1. Resource table
Unique stem cell line id-
entifier
KSCBi009-A
Alternative name(s) of s-
tem cell line
KNIH-PWS003i-A
Institution Korea National Institute of Health (KNIH)
Contact information of
distributor
Soo Kyung Koo, skkoo@korea.kr
Type of cell line iPSC
Origin Human
Additional origin info Age: 13 years
Sex: Male
Ethnicity: Korean




Transgene free Sendai virus (CytoTuneTM-iPS 2.0 Sendai
Reprogramming Kit, Life Technologies)
Genetic Modification Yes
Type of Modification Congenital
Associated disease Prader–Willi syndrome (PWS)
Gene/locus SNRPN/15q11.2-q13, deletion
Method of modification N/A






Date archived/stock date October 2017
Cell line repository/bank Deposited in the Korea Stem Cell Bank (KSCB) http://
kscr.nih.go.kr
Ethical approval KNIH Institutional Review Board (IRB) approval obtained
(2017–03–05-P-A).
Severance Children’s Hospital IRB approval obtained
(IRB No. 4–2015–0404).
2. Resource utility
Prader–Willi syndrome (PWS) is a multisystemic complex genetic
disorder characterized by the gradual development of obesity, short
stature /decreased growth velocity, and intellectual disabilities (Angulo
et al., 2015). PWS-iPSCs are patient-specific neuronal cells allowing
study of the molecular etiology of disease.
3. Resource details
PWS is caused by the absence of paternally expressed imprinted
genes at 15q11.2–q13 and paternal deletion and maternal uniparental
disomy of chromosome 15, or unbalanced paternal translocation. Most
PWS patients (70%) exhibit large deletions of the paternal 15q11.2–q13
region (Ledbetter et al., 1981). We created PWS-iPSCs by reprogram-
ming peripheral blood mononuclear cells (PBMCs) of a 13-year-old
male PWS patient with a deletion of the paternal chromosome
15q11.2–q13 region (Fig. 1 and Table 1). The iPSC line, KSCBi009-A,
exhibited normal human embryonic stem cell-like morphology and was
positive for the pluripotency markers OCT4, SSEA-4, TRA-1-60, and
https://doi.org/10.1016/j.scr.2020.101847
Received 3 December 2019; Received in revised form 21 April 2020; Accepted 11 May 2020
⁎ Corresponding authors.
E-mail addresses: skkoo@korea.kr (S.K. Koo), mihyun4868@korea.kr (M.-H. Park).
Stem Cell Research 46 (2020) 101847
Available online 20 May 2020
1873-5061/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
TRA-1-81 on immunofluorescence staining (Fig. 1A and 1B). We used
RT-qPCR employing TaqMan® probes to confirm endogenous expres-
sion of the pluripotent markers NANOG, OCT4, SOX2, TERT, REX1,
TDGF1, DNMT3B, and GDF3 (Fig. 1C). The hiPSC line exhibited a
normal karyotype (46, XY) (Fig. 1D). Deletion of the unmethylated
paternal allele was revealed using the methylation-specific multiplex
ligation probe amplification assay (MS-MLPA), to evaluate genomic
DNAs of both the donor cells and hiPSCs (Fig. 1E). At passage 10, the
KSCBi009-A line evidenced a complete absence of all exogenous
reprogramming factors (Fig. 1F). In vitro differentiation potential of the
three germ layers were evaluated via embryoid body (EB) formation.
Using TaqMan® expression probes, we confirmed that EBs expressed all
three germ layer markers: ectodermal (PAX6, NR2F2, EMX20S), meso-
dermal (T, HAND1, ITGA8), and endodermal (HNF-3β, AFP, IHH)
markers (Fig. 1G). In donor cells, the hepatitis B and C screening results
were negative (Fig. 1H). The blood group genotype was AA (Fig. 1I).
Human leukocyte antigen (HLA) class I and II typing data are shown in
Fig. 1J. Short tandem repeat (STR) analysis revealed that the KSCBi009-
Fig. 1. Characterization of iPSC line KSCBi009-A. STR analysis.
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A genotype was identical to that of donor PBMCs. We used reverse
transcription polymerase chain reaction (RT-PCR) to confirm that the
hiPSC line was free of mycoplasma contamination (Supplementary
Fig. 1).
4. Materials and methods
4.1. Ethics statements
The generation and use of human iPSCs were approved by the in-
stitutional review boards of the Severance Children’s Hospital and the
Korea National Institute of Health (KNIH). Formal informed consent
was obtained from the patient’s mother.
4.2. Reprogramming of PBMCs and hiPSC maintenance
Human peripheral blood mononuclear cells (PBMCs) from the PWS
patient were reprogrammed to develop into iPSCs using the Cytotune™-
iPS 2.0 Sendai Reprogramming Kit (Life Technologies, A16518) ac-
cording to the manufacturer's instructions. PBMCs (3 × 105 cells/mL
placed in the middle section of a 24-well plate in complete PBMC
medium) were transduced with each of four viruses (Oct3/4, KOS,
KLF4, and cMyc). The generated hiPSCs were cultured under feeder-
free conditions on Laminin-511 (Nippi, 892012)-coated plates with
StemFit Basic02 medium (Ajinomoto, AJBASIC02) supplemented with
100 ng/ml bFGF (Sigma-Aldrich, F0291) at 37 °C in a 5% CO2 atmo-
sphere. The cells were fed every other day for a week. Cells were pas-
saged at a 1:4 ratio using 0.5 mM EDTA (Invitrogen, 15575–038) with
10 μM Y-27632 (Sigma-Aldrich, Y-0503).
4.3. Immunofluorescence staining
The generated hiPSCs were fixed in 4% paraformaldehyde (Wako,
163-20145) for 20 min, blocked with 5% bovine serum albumin
(Sigma-Aldrich, A9647) with 0.25% Triton X (Sigma-Aldrich, A8787),
and incubated with primary antibodies targeting OCT4, SSEA4, TRA-1-
60, and TRA-1-81 (Table 2). Images were acquired using a fluorescence
microscope (Olympus, JP/IX83) (scale bar: 20 µm).
4.4. Real-time RT- PCR analysis
The hiPSCs were screened for endogenous expression of the plur-
ipotency markers NANOG, OCT4, SOX2, ZFP42, DMMT3B, TERT, and
TDGF1 using real-time RT-PCR. Total RNA was purified using a
Maxwell RSC simplyRNA Cells kit (Promega, AS1390), and converted to
cDNA using cDNA EcoDry Premix (Clontech, 639543). Real-time PCR
was performed using TaqMan® Gene Expression Master Mix (Applied
Biosystems, 4369510). All gene expression data were normalized to the
expression level of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The TaqMan® probes used are listed in Table 2.
4.5. Karyotyping
The karyotype was analyzed by standard cytogenetic procedures
using the GTG-band method. The cells were treated with colcemid for
45 min, incubated in hypotonic solution and fixed with methanol-acetic
acid solution (3:1). After Giemsa-trypsin banding, the karyotype was
analyzed according to the International System for Human Cytogenetic
Nomenclature using the standard G-banding method by the Molecular
Diagnostics Laboratory Service (SMLab Inc., Seoul).
4.6. MS-MLPA assay of copy number and DNA methylation status of
SNRPN
We used MS-MLPA to quantify DNA levels and determine the me-
thylation status of the PWS/AS region. Genomic DNA (gDNA) was
isolated from donor cells and iPSCs using a Maxwell RSC Blood DNA kit
(Promega, AS1400) and analyzed using the MS-MLPA ME028
Prader–Willi/Angelman probe set (MRC-Holland). The probes contain
recognition sites for HhaI, a methylation-sensitive restriction enzyme
that digests only unmethylated DNA. We evaluated copy number
changes using undigested samples and digested other samples with
HhaI to evaluate methylation status. A peak ratio of 1.0 (two copies)
associated with a methylation ratio of 0.5 (both the maternal and pa-
ternal alleles) is the wild-type scenario; a peak ratio of 0.5 (one copy)
with a methylation ratio of 0.5 (maternal allele only) indicates PWS
deletion. The x-axes show fragment sizes (bp), and the y-axes the probe
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel A
Phenotype Immunocytochemistry Positive staining for OCT4, SSEA–4, TRA–1–60, TRA–1–81 Fig. 1 panel B
RT-qPCR Expression of the pluripotency markers: NANOG, OCT4, SOX2, TERT,
REX1, TDGF1, DNMT3B, and GDF3
Fig. 1 panel C
Genotype Karyotype (G-banding) and
resolution
46XY, 500 band resolution Fig. 1 panel D
Identity Microsatellite PCR (mPCR) Not performed N/A
STR analysis 16 loci analyzed, all matched STR analysis; the data are archived
with the Journal
Mutation analysis MS-MLPA SNRPN, deletion Fig. 1 panel E
Southern blotting OR WGS Not performed N/A
Microbiology and
virology
Mycoplasma Mycoplasma-negative by RT-PCR Supplementary Fig. 1
Differentiation potential Embryoid body formation Expression of ectodermal (PAX6, NR2F2, EMX20S), mesodermal (T,
HAND1, ITGA8), and endodermal (HNF-3β, AFP, IHH) markers in
embryoid bodies
Fig. 1 panel G
Donor screening HIV 1 + 2, hepatitis B, hepatitis C HIV 1 + 2: Not performed
Hepatitis B, hepatitis C: Negative
Fig. 1 panel H
Genotype additional info Blood group genotyping DNA analysis
AA
Fig. 1 panel I
HLA tissue typing A* 02:01/02:01
B* 46:01/51:01
DRB1* 08:03/12:01
Fig. 1 panel J
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peak ratios. Blue: internal control probes; red: PWS/AS probes; green:
the five HhaI methylation-sensitive probes (Procter et al. (2006)).
4.7. Detection of the reprogramming vector
To test whether transgenes were silenced, hiPSCs at passage 10 were
confirmed by RT-PCR. Total RNA was isolated using a Maxwell RSC
simplyRNA Cells Kit (Promega, AS1390), and cDNA was synthesized by
reverse transcription of RNA employing cDNA EcoDry Premix
(Clontech, 639543). Primers specific to the SeV genome are listed in
Table 2. GAPDH was amplified concurrently and used as an internal
control.
4.8. In vitro differentiation assay
The in vitro differentiation potential of KSCBi009-A cells was eval-
uated using an EB formation assay. EBs were cultivated in EB medium
comprised of Dulbecco's modified Eagle's medium (DMEM)/F12
medium (Gibco, 11320-082) with 20% knockout serum replacement
(Gibco, 10828-028), 1% nonessential amino acids (Gibco, 11140-050),
and 0.1 mM β-mercaptoethanol (Gibco, 21985-023) for 14 days.
Differentiated cells were analyzed by RT-qPCR using TaqMan® Gene
Expression Master Mix (Applied Biosystems, 4369510). The TaqMan®
probes used are listed in Table 2.
4.9. Donor screening, blood group genotyping and HLA tissue typing
Hepatitis B and C screening of donor cells, blood group genotyping,
and human leukocyte antigen (HLA) tissue typing were performed by
the Molecular Diagnostics Laboratory Service (SMLab Inc., Seoul).
4.10. STR analysis
Short tandem repeat (STR) analysis was performed on generated
hiPSCs and donor cells using the PowerPlex®16 System (Promega) to
detect 16 loci: D3S1358, TH01, D21S11, D18S51, PentaE, D5S818,
D13S317, D7S820, D16S539, CSF1PO, PentaD, vWA, D8S1179, TPOX,
FGA, and Amelogenin by the Molecular Diagnostics Laboratory Service
(SMLab Inc., Seoul).
4.11. Mycoplasma test
Mycoplasma contamination status in culture medium was evaluated
using a PCR Mycoplasma Detection Set (Takara, 6601) according to the
manufacturer’s instructions. Amplified DNA was subjected to 1.5%
agarose gel electrophoresis.
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Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Rabbit anti-OCT3/4 1:200 Santa Cruz Cat# sc-9081, RRID:AB_2167703
Mouse anti-SSEA4 1:200 Millipore Cat# MAB4304, RRID:AB_177629
Mouse anti-TRA–1–60 1:200 Millipore Cat# MAB4360, RRID:AB_2119183
Mouse anti-TRA–1–81 1:200 Millipore Cat# MAB4381, RRID:AB_177638
Secondary antibodies Alexa Fluor 488 donkey anti-rabbit IgG (H + L) 1:500 Thermo Fisher Scientific, Cat# A21206, RRID:AB_2535792
Alexa Fluor 488 donkey anti-mouse IgG (H + L) 1:500 Thermo Fisher Scientific, Cat# A21203, RRID:AB_2535789
Primers
Target Forward/Reverse primer (5′-3′)
SeV transgene detection (RT-PCR) SeV /181 bp GGA TCA CTA GGT GAT ATC GAG C*/ACC AGA CAA GAG TTT AAG AGA TAT GTA TC*
KOS/528 bp ATG CAC CGC TAC GAC GTG AGC GC/ACC TTG ACA ATC CTG ATG TGG
KLF4/410 bp TTC CTG CAT GCC AGA GGA GCC C/AAT GTA TCG AAG GTG CTC AA*
c-MYC/532 bp TAA CTG ACT AGC AGG CTT GTC G*/TCC ACA TAC AGT CCT GGA TGA TG
Housekeeping gene (RT-PCR) GAPDH CAT GTT CGT CAT GGG TGT GAA/GGA CTG TGG TCA TGA GTC CTT
Pluripotency markers (qPCR) NANOG TaqMan Probe ID Hs02387400-g1
OCT4 TaqMan Probe ID Hs00742896-s1
SOX2 TaqMan Probe ID Hs00602736-s1
TERT TaqMan Probe ID Hs00162669-m1
TDGF1 TaqMan Probe ID Hs02339499-g1
DNMT3B TaqMan Probe ID Hs00171876-m1
REX1 TaqMan Probe ID Hs00399279-m1
Differentiation markers (qPCR) PAX6 TaqMan Probe ID Hs00240871-m1
NR2F2 TaqMan Probe ID Hs01047078-m1
EMX2OS TaqMan Probe ID Hs01393139-m1
T TaqMan Probe ID Hs00610080-m1
HAND1 TaqMan Probe ID Hs02330376-s1
ITGA8 TaqMan Probe ID Hs00233321-m1
HNF-3β TaqMan Probe ID Hs00232764-m1
AFP TaqMan Probe ID Hs00173490-m1
IHH TaqMan Probe ID Hs00745531-s1
Housekeeping gene (qPCR) GAPDH TaqMan Probe ID Hs99999905-m1
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2020.101847.
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